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Dermatofibrosarcoma protuberans is a rare soft tissue tu-
mour, for which the quality of care is poorly studied. Ra-
tes of re-excision and recurrence were determined using 
data from the Netherlands Cancer Registry between 1989 
and 2016. Of the 1,890 dermatofibrosarcoma protuberans 
included, 87% were treated with excision, 4% with Mohs 
micrographic surgery, and 9% otherwise or unknown. Half 
of all excisions (847/1,644) were incomplete and 29% 
(192/622) of all re-excisions were incomplete. Of the pa-
tients who received surgery, 7% needed multiple surgeries. 
Due to the high rate of incomplete excisions and recurren-
ces after excision, this study supports the European gui-
deline, which recommends treating dermatofibrosarcoma 
protuberans with Mohs micrographic surgery in order to 
increase the quality of care.
Dermatofibrosarcoma protuberans is a rare soft tissue 
tumour with a very low (< 0.5%) rate of metastasis. 
Rates of re-excision and recurrence were determined 
using data from the Netherlands Cancer Registry bet-
ween 1989 and 2016. Of the 1,890 instances of der-
matofibrosarcoma protuberans included, 87% were 
treated with excision, 4% with Mohs micrographic 
surgery, and 9% otherwise or unknown. Linked pat-
hology data were retrieved for 1,677 patients. Half of 
all excisions (847/1,644) were incomplete and 29% 
(192/622) of all re-excisions were incomplete. The 
cumulative incidence of a recurrence was 7% (95% 
confidence interval (CI) 6–8) during a median follow-
up of 11 years (interquartile range (IQR) 6–17). After 
Mohs micrographic surgery (n = 34), there were no re-
currences during a median follow-up of 4 years (IQR 
3–6). Due to the high rate of incomplete excisions and 
recurrences after excision, this study supports the Eu-
ropean guideline, which recommends treating derma-
tofibrosarcoma protuberans with Mohs micrographic 
surgery in order to decrease the rate of recurrence.
Key words: dermatofibrosarcoma protuberans; recurrence; 
surgical excision; histological clearance; Mohs micrographic 
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Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue tumour that originates from a transloca-
tion of chromosomes 17 and 22, resulting in tumour cell 
proliferation of fibrohistiocytic lineage (1). Unlike most 
skin cancers, DFSP is a non-UV-related skin cancer (1). 
The overall standardized incidence rate in the Nether-
lands and the USA is 4 per 1,000,000 person-years (2–4). 
Men and women are equally affected, and the peak in-
cidence age is between 20 and 50 years (5–7). Although 
DFSP occurs mostly in adult patients, it rarely occurs in 
children until 20 years old in the USA (1.0 per 1 million) 
(8). DFSP is commonly located on the trunk (50%), prox-
imal extremities (20–30%) or head and neck (10–15%) 
(5–7). It presents as an asymptomatic, slowly growing, 
skin-coloured indurated plaque. Al though DFSPs rarely 
metastasize, they grow in a locally invasive manner into 
subcutaneous fat, muscles and sometimes bone (5, 6, 9). 
Clinically, and with imaging tests (e.g. magnetic reso-
nance imaging (MRI) or computed tomography (CT)), 
DFSP are difficult to delineate because the tentacle-like 
invasion into subcutaneous tissue is often greater than 
suspected. As a result, multiple surgical procedures may 
be required to ensure complete clearance of DFSP.
Until 2015, DFSP guidelines were lacking and, in the 
Netherlands, the majority of DFSPs were treated with 
standard excision. The European consensus-based inter-
disciplinary guideline, which has been available since 
2015, recommends treating DFSPs with Mohs micro-
graphic surgery (MMS) in order to reduce the assumed 
high recurrence rate after standard excision (10).
To date, outcome data for management of DFSPs are 
based on small cohorts of patients, with limited informa-
tion on those lost to follow-up (6, 11). Previous studies 
report a wide range of rates of re-excision (3–81%) and 
recurrence (0–46%) of DFSP (6, 7, 9, 12, 13). This na-
tionwide cohort study of DFSP with long-term follow-up 
aims to determine the rate of re-excision and recurrence, 
which is needed to inform patients, clinicians, and health 
policymakers in planning optimal treatment strategies 
and surveillance schedules.
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This cohort study included all patients with a histologically 
confirmed DFSP in the Netherlands between January 1989 and 
December 2016 (Fig. 1). Data were obtained from the Netherlands 
Cancer Registry (NCR), which has collected data on all newly di-
agnosed cancer patients in the Netherlands since 1989. Registration 
is based primarily on notification by the nationwide network and 
registry of histopathology and cytopathology (PALGA), which 
contains all pathology reports of all Dutch pathology laboratories. 
Completeness of NCR incidence data on cutaneous malignancies is 
93% (14). All data used for this study from the NCR (i.e. patients’ 
sex and age, DFSP location, type of treatment and physician) were 
collected from the medical records of hospitals by specially trai-
ned NCR employees. Tumour localization and morphology were 
registered according to the International Classification of Diseases 
for Oncology (ICD-O-3). Location of the primary tumour was 
categorized into face/scalp/neck (C44.0–C44.4), trunk (C44.5), 
arm/shoulder (C44.6), leg/hip (C44.7), genital (C51.0, C51.9, 
C63.2) or other (C44.8, C44.9). Vital status and date of death 
or emigration of the included patients were obtained by annual 
linkage with the Dutch Municipality Registers.
Study outcome
The outcome of interest was the rate of incomplete excisions and 
recurrences of DFSPs. The NCR registers DFSP only at the time 
of first primary diagnosis. Therefore, to detect all re-excisions and 
recurrences during follow-up, the included patients from the NCR 
registry were linked to PALGA. In order to have at least 2 years 
of follow-up, PALGA data were retrieved only for patients who 
were diagnosed with a DFSP before 1 January 2014. Follow-up of 
the patients started on the day of the first primary DFSP diagnosis 
and ended on the day of death or emigration, or the last date of 
NCR-PALGA linkage, which, for this study, was performed on 
1 February 2015.
Conclusions from the PALGA pathology reports were reviewed 
manually (WK, EIVC, LH, CBVL) and scored on the following 
variables: diagnosis (DFSP, possible DFSP, other), immunohisto-
chemical staining with CD34 (positive, negative, not performed), 
anatomical location (according to ICD-O-3), type of specimen 
(biopsy, diagnostic excision, wide local excision, re-excision, 
MMS, Breuninger surgery, other, unclear), histological clearance 
(yes, no, unknown, not applicable in the case of diagnostic biop-
sies), invasion into muscle (yes, no, possibly), fibrosarcomatous 
changes (yes, no, possibly) and clinical excision margins (in mm) 
(1). Invasion into muscle, immunohistochemistry for CD34, fibro-
sarcomatous changes and clinical excision margins were missing 
for 50–99% of cases and therefore not included in the final analysis. 
All pathology reports with uncertain DFSP diagnosis (i.e. when 
the pathologist was in doubt about the diagnosis or if the pathology 
report was unclear) were excluded from the analyses (n = 297). 
Incompletely excised DFSP included DFSP that histologically 
invaded the inked surgical margin. Local DFSP recurrence inclu-
ded histologically proven DFSP that occurred at least 4 months 
after the previous pathology report, because it was assumed that 
re-excisions would occur within this period.
Statistical analysis
Annual incidence rates were calculated by sex, age groups and 
body sites per 1,000,000 person-years from 1989 to 2016, using 
the annual population size acquired from Statistics Netherlands 
(https://opendata.cbs.nl/statline/#/CBS/en/). Standardized inci-
dence rates were calculated using the European standard popula-
tion (2013) (15). Descriptive statistics were used to report the 
baseline characteristics of patients, DFSP, treatment and study 
outcome. In order to estimate the number of surgical procedures 
during follow-up (i.e. including the first surgical treatment of the 
primary DFSP and all re-excisions and/or recurrences), the mean 
cumulative count was calculated, which is equal to the sum of the 
cumulative incidences of all surgical procedures (16). To estimate 
the probability of the first DFSP recurrence during follow-up, a 
cumulative incidence curve (CIC) was calculated, which takes the 
competing risk of death into account (17). Statistical analyses were 
performed using STATA (version 15), SAS 9.4 statistical software 
(SAS Institute Inc., Cary, NC, USA), R statistical software version 
3.4.1 (www.r-project.org). p-values < 0.05 (2-sided) were consi-
dered statistically significant.
RESULTS
Incidence and treatment of the first dermatofibrosarcoma 
protuberans
A total of 1,890 patients were diagnosed with 
a DFSP in the Netherlands between 1989 and 
2016 (Table I). Both the crude and European 
standardized incidence rate of DFSP were 4.2 
per 1,000,000 person-years (Table II). The 
incidence rate of DFSP was stable between 
1989 and 2016. Incidence rates were compa-
rable for men and women. Half of the 1,890 
patients with a DFSP were men (49%) and 
overall median age at diagnosis was 41 years 
(IQR 31–41). DFSP were most commonly 
located on the trunk (45%) followed by arm/
shoulder (24%), leg/hip (16%), head and neck 
(13%) and genital area (1%) (Table I). 
The majority of the 1,890 patients with 
a primary DFSP were treated with excision 
Fig. 1. Flowchart of materials and methods. DFSP: dermatofibroma 
sarcoma protuberans; NCR: Netherlands Cancer Registry; PALGA: Dutch 
nationwide pathology database.
Inclusion of NCR data of all patients with primary DFSP between 1989-2016
n=1,890 patients
Analyses of Incidence rates
n=1,890 patients



















Excluded reports after manual review 
(n=3,752)
- Not DFSP reports (n=2,783)
- Uncertain DFSP  reports (n=297)
- Revision of DFSP report (n=624)
- Multiple reports of MMS on the
same day (n=39)
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(87%). Data from the NCR on the first primary DFSP 
showed that more than half of the 1,890 patients (56%) 
underwent a single excision, whereas 25% underwent 2 
excisions and 6% underwent 3 or more excisions. Only 
4% of patients underwent MMS as a primary treatment 
or as additional treatment after excision, and 1% were 
not treated at all. Non-surgical treatments included 
postoperative radiotherapy (6%) and or other types of 
treatment, such as tyrosine kinase inhibitors (1%). The 
majority of first treatments for DFSPs were performed 
by surgeons (38%), while dermatologists treated only 
11% of DFSPs. The other DFSPs were treated by plastic 
surgeons (6%), or general practitioners (2%), or by phy-
sicians who worked in a multidisciplinary team (13%), 
or it was unknown (30%).
Re-excisions
For 1,677 patients who were diagnosed between 1989 
and 2013, linked pathology data were retrieved from 
PALGA (Table III). Patient and tumour characteristics 
were similar to patients without linked pathology data 
(data not shown). Of the 1,677 patients, 35% underwent 
a single surgical treatment for a primary DFPS during 
a median follow-up of 11 years (IQR 6–17). Half of 
all patients (51%: (588+180+78)/1,677) underwent 
Table I. Characteristics of patients diagnosed with a primary 
dermatofibrosarcoma protuberans (DFSP) in the Netherlands 






  Men 926 (49)
  Women 964 (51)
Age
  0–19 years 114 (6)
  20–39 years 741 (39)
  40–59 years 718 (38)
  60–79 years 257 (14)
  ≥ 80 years   60 (3)
Anatomical location
  Trunk 848 (45)
  Arms/shoulder 463 (24)
  Leg/hips 305 (16)
  Face/scalp/neck 239 (13)
  Genitals   12 (1)
  Other   20 (1)
  Unknown     3 (0)
Surgical treatment for first primary DFSP
  1 excision 1,053 (56)
  2 excisions 469 (25)
  ≥3 excisions 109 (6)
  Mohs micrographic surgery   81 (4)
Non-surgical treatment
  Postoperative radiotherapy 119 (6)
  Othersa   18 (1)
  Unknown   15 (1)
  No treatment   14 (1)
Physician
  Surgeon 707 (38)
  Dermatologist 209 (11)
  Plastic surgeon 105 (6)
  General practitioner   42 (2)
  Multidisciplinary 240 (13)
  Unknown 591 (30)
aOthers included, e.g. tyrosine kinase inhibitors.
Percentages were rounded.
Table III. Re-excision and recurrence of dermatofibrosarcoma 
protuberans with a primary diagnosis between 1989 and 2013 for 
whom follow-up data until 31 December 2015 were retrieved from 
the Dutch nationwide pathology database (PALGA) 
DFSP patients 1989–2013
n = 1,677
Follow-up, years, median (IQR) 10.5 (5.6–16.6)
Surgical treatments during follow-upa, n (%)
  1 591 (35)
  2 588 (35)
  3 180 (11)
  ≥ 4 78 (5)
  Unknown 240 (14)
Recurrences, n (%)
  None 1,517 (90)
  1 145 (9)
  ≥ 2 15 (1)
aSurgical treatments during follow-up excluded biopsies, treatments of primary 
DFSPs, and treatments of cases of which the histological DFSP diagnosis was 
unclear. Surgical treatments included and Mohs micrographic surgery (n = 34).
Percentages were rounded.






(ESR2013) ESR (1976) WSR (1968)
WSR
2000–2025 US2000SR CAN1996SR
Overall 4.22 4.20 4.03 3.58 3.85 4.09 4.20
Sex
  Men 4.18 4.27 3.98 3.51 3.77 4.07 4.18
  Women 4.26 4.21 4.19 3.69 3.96 4.17 4.26
Age group
  0–19 years 1.05 1.06 1.02 0.98 1.03 1.05 1.05
  20–39 years 5.78 5.77 5.71 5.57 5.65 5.78 5.85
  40–59 years 5.82 5.76 5.78 5.85 5.85 5.89 5.91
  60–79 years 3.55 3.53 3.56 3.56 3.56 3.54 3.53
  ≥80 years 3.83 3.84 3.85 3.85 3.85 3.85 3.85
Body site
  Skin, head/face/neck 0.53 0.58 0.48 0.41 0.44 0.50 0.50
  Skin, trunk 1.89 1.88 1.83 1.64 1.75 1.83 1.87
  Skin, arm/shoulder 1.04 1.01 1.01 0.92 0.98 1.00 1.03
  Skin, leg/hip 0.68 0.67 0.67 0.62 0.65 0.66 0.68
  Skin other/unknown 0.04 0.04 0.05 0.05 0.05 0.05 0.05
  Genital 0.03 0.03 0.02 0.02 0.02 0.02 0.02
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multiple surgical treatments. The number of surgical 
treatments was unknown for 14% (n = 240) of all pa-
tients. Of all 1,644 pathology reports of DFSP excisions, 
32% (n = 524) were completely excised, 52% (n = 847) 
were incompletely excised and histological clearance 
was unknown for 17% (n = 273) of all reports. Of all 
662 pathology reports of DFSP re-excisions, 61% 
(n = 401) were completely excised, 29% (n = 192) were 
incompletely excised and histological clearance was 
unknown for 69 reports (10%). The mean cumulative 
count of surgical treatments per patient was 1.4 (95% 
CI 1.3–1.4) after a follow-up of 6 months, and remained 
stable thereafter (Fig. 2).
Recurrences
During a median follow-up of 11 years (IQR 6–17), 9% 
(n = 145) of 1,677 patients experienced one local recur-
rence and 1% (n = 15) of patients had two or more local 
recurrences. The cumulative incidence curve showed 
that the majority of recurrences occurred within 5 years 
(n = 98/128, 77%). However, some recurrences occurred 
even after 10 years (Fig. 3). After 20 years of follow-up, 
the cumulative incidence of local recurrence was 7% 
(95% CI 6–8). None of the 34 patients who underwent 
MMS between 1989 and 2013, experienced any recur-
rence during a median follow-up of 4 years (IQR 3–6).
DISCUSSION
This large nationwide cohort study of patients with DFSP 
shows that the efficacy of excision is poor given the 
high rate of patients who underwent multiple surgical 
excisions (51%) to clear all tumour cells. This study 
also showed that 10% of all patients experienced at least 
one recurrence during a median follow-up of 11 years 
(IQR 6–17).
Incidence and treatment of the first dermatofibrosarcoma 
protuberans
In concordance with other studies, the ratio of incidence 
rates for men and women was 1:1. The majority of DFSPs 
occurred among young people (median age 41 years), and 
the most common location was the trunk (45%) (5, 6).
The majority of DFSP excisions were performed by 
surgeons. This is probably due to the referral pattern of 
general practitioners in the Netherlands, who tend to refer 
patients with a sarcoma or a relatively large tumour to sur-
geons. Ideally, these patients are referred to dermatologists 
in specialized centres where multidisciplinary experts 
work together in order to plan optimal treatment strategies.
While the European guideline recommends treating 
DFSPs with MMS, this study shows that only 4% of all 
DFSPs were treated with MMS (10). The low percentage 
of patients treated with MMS is due to the introduction 
of the Dutch guideline in 2015 (while the cases were 
included between 1989 and 2016) and only in a single 
university medical centre have DFSPs been treated with 
MMS since 2008. 
Only a few cases were treated with postoperative 
radiotherapy in our study, probably because it is still 
unclear whether radiotherapy is effective in slowly 
growing tumours, such as DFSP. Also, only a few cases 
were treated with tyrosine kinase inhibitors (imatinib), 
probably because systemic treatment for DFSP is indi-
cated only for metastasized tumours or for tumours that 
could not be treated surgically, which is rarely the case 
for DFSPs (18, 19).
Fig. 2. Mean cumulative count of surgical treatments of 
dermatofibrosarcoma protuberans (DFSP), which were diagnosed 
between 1989 and 2013 and followed-up until 2015 using data from 
the Dutch nationwide pathology database. The majority of surgical 
treatments occurred within the first 6 months (vertical line).
Fig. 3. Cumulative incidence curve of the first recurrence 
with 95% confidence interval of dermatofibrosarcoma 
protuberans, which were diagnosed between 1989 and 
2013 and followed-up until 2015 using data from the 
Dutch nationwide pathology database. The majority of 
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(Re)-excisions
We observed that, in our large population-based sample, 
51% of DFSPs were re-excised and 10% recurred. Ra-
tes of re-excision and recurrence vary widely between 
studies; between 3–81% and 0–46%, respectively (6, 
7, 9, 12, 13). This variation is most likely due to the 
small cohort size of the studies (range 14–451) (6, 11), 
and to the heterogeneity of included patients regarding 
anatomical locations (e.g. head and neck only vs. all 
body sites), surgical treatments used (e.g. wide local 
excision vs. MMS), clinical excision margin size (e.g. 
small vs. wide), physician (e.g. surgeon, plastic surgeon, 
dermatologist), methodology of collecting follow-up 
data (e.g. from the patient files, patients consultation by 
phone or doctor’s visit), length of follow-up (few months 
up to several years) and numbers of patients lost during 
follow-up (often not specified).
The observed DFSP re-excision rate of 51% is much 
higher than the known re-excision rates for basal cell 
carcinoma (BCC) (7–30%) (20) and squamous cell 
carcinoma (SCC) (0–25%) (21, 22). Multiple aspects 
contribute to the high re-excision rate for DFSP com-
pared with BCC and SCC. First, DFSP is a rare tumour 
and therefore physicians may be less familiar with the 
clinical recognition and delineation of the extent of a 
DFSP. Secondly, physicians who are experienced in 
treating DFSP also find it difficult to delineate the extent 
of a DFSP preoperatively because of the subcutaneous 
tentacle-like invasion, which might be invisible to the 
naked eye both clinically and on imaging tests (e.g. MRI 
or CT). Thirdly, DFSP does not grow in a symmetrical 
manner around the clinically visible centre. Therefore, 
a clinically tumour-free margin even up to several centi-
metres around the clinically visible tumour centre often 
results in histologically tumour-positive margins on one 
side of the tumour, while on the other side healthy tissue 
is unnecessarily excised.
Recurrences
Although our observed recurrence rate of DFSP during 
a median follow-up period of 11 years (IQR 6–17) of 
10% is within the range of known recurrence rates for 
BCC (12%) (23), SCC (10%) (21, 22) and melanoma 
(12%) (24), a recurrence rate of 7% is clinically relevant 
(21–24). It is most likely that histopathological missed 
residual tumour continued to grow and presented in 
time as a recurrent DFSP. DFSP might be absent on the 
evaluated slides, while still being present in the patient, 
because, with the standardized bread loaf technique, only 
a few vertical slides through the excised specimen are 
examined, representing only a small portion of the true 
excision margins.
Although this study presented only 34 patients who 
were treated with MMS, none of the patients developed 
a recurrence during a median follow-up of 4 years (IQR 
3–6), which is in line with other studies. A possible lack 
of aggressiveness of DFSPs treated with MMS compared 
with DFSPs treated with standard excision, cannot ex-
plain this finding, because only a single university centre 
performed MMS for all DFPs treated in their centre since 
2007. Other university centres performed standard exci-
sion for DFSPs. There were thus no referral patterns that 
could explain this finding. Therefore, our results suggest 
that MMS is an appropriate treatment for DFSP (25–28).
The observation that the majority of DFSP recurrences 
occurred within the first 5 years of follow-up is in line 
with the literature (5, 6) and implies that follow-up of 
at least 5 years is reasonable, especially because of the 
difficulty of distinguishing a nodal origin from scar tissue 
or from a recurrence. 
Strengths and limitations
Strengths of this study are the use of nationwide cancer 
registry data, which resulted in a large number of cases 
of DFSP, a robust data-set to detect re-excision and recur-
rence rates using the nationwide pathology database, and 
the long-term follow-up period (up to 26 years). Limita-
tions include a lack of information concerning high-risk 
features for most pathology reports, such as invasion into 
muscle and fibrosarcomatous changes. Another limitation 
is that 17% of the pathology reports of primary excisions 
and 10% of the pathology reports of re-excisions did not 
contain conclusive information on histological clearance. 
Therefore, the rate of incomplete excisions and recur-
rence of DFSP was probably underestimated.
Conclusion
This study reports a high rate of incomplete excisions 
of DFSP (51%) and a clinically relevant high recur-
rence rate (10%) during a median follow-up of 11 years. 
Multiple surgical procedures can lead to poor functional 
and cosmetic outcomes for patients, with higher costs to 
society. This study shows that there is a need to improve 
the quality of care for DFSP, and the results support the 
current European guideline, which recommends treating 
DFSPs with MMS instead of excision (10). 
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